Tarsus Pharmaceuticals, Inc.(TARS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

TARS Tarsus Pharmaceuticals, Inc.

Market Closed 04-11 16:00:00 EDT

46.43

+2.31

+5.24%

盘后46.43

+0.000.00%

19:06 EDT

High46.59	Low42.90	Vol781.14K
Open43.93	D1 Closing44.12	Amplitude8.37%
Mkt Cap1.93B	Tradable Cap1.49B	Total Shares41.61M
T/O35.16M	T/O Rate2.44%	Tradable Shares32.01M
P/B8.60	ROE-54.83%	EPS-3.07
52wk High57.28	52wk Low20.08	P/E-15.11
Dividend0.00	Div.Yield0.00	ROA-23.46%

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"TARS","market":"US","secType":"STK","nameCN":"Tarsus Pharmaceuticals, Inc.","latestPrice":46.43,"timestamp":1744401600000,"preClose":44.12,"halted":0,"volume":781139,"hourTrading":{"tag":"盘后","latestPrice":46.43,"preClose":46.43,"latestTime":"19:06 EDT","volume":28237,"amount":1311044.16,"timestamp":1744412786233},"delay":0,"floatShares":32005800,"shares":41607514,"eps":-3.072873,"marketStatus":"Market Closed","change":2.31,"latestTime":"04-11 16:00:00 EDT","open":43.93,"high":46.59,"low":42.895,"amount":35162905.688185,"amplitude":0.083749,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.072873,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1744617600000},"marketStatusCode":7,"adr":0,"listingDate":1602820800000,"exchange":"NASDAQ","adjPreClose":44.12,"preHourTrading":{"tag":"盘前","latestPrice":43.5,"preClose":44.12,"latestTime":"07:51 EDT","volume":112,"amount":4857.319824,"timestamp":1744372305020},"postHourTrading":{"tag":"盘后","latestPrice":46.43,"preClose":46.43,"latestTime":"19:06 EDT","volume":28237,"amount":1311044.16,"timestamp":1744412786233},"volumeRatio":0.901173544129541,"impliedVol":0.5447,"impliedVolPercentile":0.0876},"requestUrl":"/m/hq/s/TARS/tweets","defaultTab":"tweets","newsList":[{"id":"2524640417","title":"With Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) It Looks Like You'll Get What You Pay For","url":"https://stock-news.laohu8.com/highlight/detail?id=2524640417","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524640417?lang=en_us&edition=full_marsco","pubTime":"2025-04-02 19:52","pubTimestamp":1743594766,"startTime":"0","endTime":"0","summary":"Tarsus Pharmaceuticals, Inc.'s ( NASDAQ:TARS ) price-to-sales (or \"P/S\") ratio of 10.3x might make it look like a...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tars/tarsus-pharmaceuticals/news/with-tarsus-pharmaceuticals-inc-nasdaqtars-it-looks-like-you","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["QLD","IE00BGHQF748.EUR","PSQ","TQQQ","BK4112","MNQmain","IE00B3QW5Z07.USD","IE00BKPKM429.USD","USJW.SI","QID","SQQQ","NQmain","BK4007","NDAQ","TARS","TSYW.SI","USAW.SI","BK4588","LU2210149790.SGD","LU2095319765.USD",".IXIC","LU2210150020.SGD","NVIW.SI","BK4585","IE00B64PRP62.GBP"],"gpt_icon":1},{"id":"2522794255","title":"Oppenheimer Sticks to Its Buy Rating for Tarsus Pharmaceuticals (TARS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2522794255","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522794255?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 20:47","pubTimestamp":1743166054,"startTime":"0","endTime":"0","summary":"In a report released today, Francois Brisebois from Oppenheimer maintained a Buy rating on Tarsus Pharmaceuticals (TARS – Research Report), with a ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/oppenheimer-sticks-to-its-buy-rating-for-tarsus-pharmaceuticals-tars-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/oppenheimer-sticks-to-its-buy-rating-for-tarsus-pharmaceuticals-tars-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TARS","OPY"],"gpt_icon":0},{"id":"2519856750","title":"BUZZ-U.S. STOCKS ON THE MOVE-Metropolitan Bank, Fossil, MeiraGTx","url":"https://stock-news.laohu8.com/highlight/detail?id=2519856750","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519856750?lang=en_us&edition=full_marsco","pubTime":"2025-03-13 23:47","pubTimestamp":1741880850,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Metropolitan Bank, Fossil, MeiraGTxEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250313:nL4N3PW19Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2250418816.HKD","IE00BJJMRX11.SGD","MCB","BK4570","AEO","NEM","KNSA","LU2430703178.SGD","PCAR","BBW","FOSL","NOVA","AEYE","DLTR","ATEN","LU0162691827.USD","IE00BMPRXQ63.HKD","SPIR","LU0238689110.USD","MGTX","LU2065169927.USD","LU1496350171.SGD","LU2498475776.HKD","ETNB","GIII","LU1043141123.HKD","LU2317271919.USD","NN","TARS","LYV","AVAH","NVAX","TRIB","APGE","KYMR","ALKT","LU2506952170.USD","MNTK","LU0276348264.USD","LU0096364046.USD"],"gpt_icon":1},{"id":"2519831237","title":"Sector Update: Health Care Stocks Flat to Lower Premarket Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=2519831237","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519831237?lang=en_us&edition=full_marsco","pubTime":"2025-03-13 21:11","pubTimestamp":1741871495,"startTime":"0","endTime":"0","summary":"Health care stocks were flat to lower premarket Thursday as the iShares Biotechnology ETF  was inactive and the Health Care Select Sector SPDR Fund  was recently down 0.3%.ImmunoPrecise Antibodies  shares rallied past 14% after the company announced a strategic partnership with an unnamed biotechnology company to discover and develop antibody-drug conjugates and bispecific antibodies to treat cancer.Integer Holdings  shares were down nearly 2% amid plans to offer $750 million of convertible notes due 2030.Tarsus Pharmaceuticals  shares were almost 3% lower after the company priced an upsized underwritten public offering of 2.8 million shares at $44.50 per share for gross proceeds of about $125 million.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1815336091.USD","LU0566484027.USD","BK4082","LU1169589451.USD","XLV","BK4588","ITGR","BK4121","LU0029874061.USD","IPA","BK4585","LU1169590202.USD","LU0757428866.USD","LU0128526141.USD","LU1559883803.SGD","BK4007","BK4581","IBB","TARS"],"gpt_icon":0},{"id":"2519534836","title":"BUZZ-Tarsus Pharma dips after upsized $125 mln stock offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2519534836","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519534836?lang=en_us&edition=full_marsco","pubTime":"2025-03-13 20:23","pubTimestamp":1741868605,"startTime":"0","endTime":"0","summary":"BUZZ-Tarsus Pharma dips after upsized $125 mln stock offering**  Shares of Tarsus Pharmaceuticals TARS.O down 2.9% to $45.75 before the bell as co raises more equity than targeted** Irvine, California-based co late Weds sold ~2.8 mln shares at $44.50 for $125 mln gross proceeds** Offering size increased from $100 mln, priced at 5.5% discount to last sale** Co intends to use net offering proceeds to advance commercialization of its eye care drug, XDEMVY, develop its product pipeline, among other purposes** With ~38.3 mln shares outstanding, co has $1.8 bln market cap** Goldman Sachs, BofA, Barclays and Oppenheimer jt bookrunners for the offering** Through Weds, stock down 15% YTD. Shares have risen roughly 50% over the past six months** Avg rating among 8 analysts is \"buy\"; median PT of $71 implies ~51% upside to stock's last close - LSEG data","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250313:nL6N3PW0IL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1868836914.USD","LU2750360641.GBP","LU2471134796.USD","LU2471134879.HKD","BK4127","BK4516","LU1868836591.USD","IE00BFXG1179.USD","LU2471134952.CNY","BK4552","IE00B19Z3581.USD","LU1791807156.HKD","TARS","LU1668664300.SGD","BK4007","LU2237443622.USD","BK4504","IE00BSNM7G36.USD","LU2237443978.SGD","IE0034235188.USD","LU0106831901.USD","IE00B19Z3B42.SGD","LU1868836757.USD","IE0004086264.USD","BK4588","BK4585","LU2237443382.USD","LU0096364046.USD","IE0002270589.USD","BK4533","LU2237443895.HKD","LU2471134523.USD","LU2750360997.AUD","LU2237438978.USD","LU1868837136.USD","LU2237443465.HKD","LU0061475181.USD","LU1868837300.USD","BK4550","LU2237443549.SGD","IE0004091025.USD"],"gpt_icon":0},{"id":"2519000674","title":"Tarsus Pharmaceuticals Prices Upsized $125 Million Equity Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2519000674","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519000674?lang=en_us&edition=full_marsco","pubTime":"2025-03-13 15:43","pubTimestamp":1741851806,"startTime":"0","endTime":"0","summary":"Tarsus Pharmaceuticals (TARS) said late Wednesday it has priced an upsized underwritten public offering of 2.8 million shares at $44.50 per share for gross proceeds of about $125 million.Underwriters ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","BK4215","TARS","BK4007","BK4588","EQR"],"gpt_icon":0},{"id":"2517125290","title":"Tarsus Pharmaceuticals Inc : Jefferies Raises Target Price to $58 From $54","url":"https://stock-news.laohu8.com/highlight/detail?id=2517125290","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517125290?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 12:25","pubTimestamp":1741321553,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250307:nFWN3PP1FX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TARS","BK4007"],"gpt_icon":0},{"id":"2517114019","title":"Tarsus Pharmaceuticals Is Maintained at Buy by Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2517114019","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517114019?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 07:10","pubTimestamp":1741302600,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TARS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 06, 2025 18:10 ET (23:10 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TARS"],"gpt_icon":0},{"id":"2517736116","title":"Tarsus to Participate in Upcoming Investor Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2517736116","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517736116?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 06:00","pubTimestamp":1741298400,"startTime":"0","endTime":"0","summary":"IRVINE, Calif., March 06, 2025  -- Tarsus Pharmaceuticals, Inc. , today announced that management will participate in a fireside chat at the Barclays 27th Annual Global Healthcare Conference on Tuesday, March 11th, at 8:00 a.m. / 11:00 a.m. ET.A live webcast and additional information can be accessed on the events section of the Tarsus website. The replay will be available on the Tarsus website within 48 hours and will be archived for a limited time.About Tarsus Pharmaceuticals, Inc.Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care and infectious disease prevention. XDEMVY  is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tarsus-participate-upcoming-investor-conference-220000742.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","TARS"],"gpt_icon":0},{"id":"2517961591","title":"Tarsus Pharmaceuticals price target raised to $58 from $54 at Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2517961591","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517961591?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 02:16","pubTimestamp":1741284968,"startTime":"0","endTime":"0","summary":"Jefferies raised the firm’s price target on Tarsus Pharmaceuticals (TARS) to $58 from $54 and keeps a Buy rating on the shares. The firm says it is...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tarsus-pharmaceuticals-price-target-raised-to-58-from-54-at-jefferies?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tarsus-pharmaceuticals-price-target-raised-to-58-from-54-at-jefferies?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TARS"],"gpt_icon":0},{"id":"2517418569","title":"Barclays Sticks to Their Buy Rating for Tarsus Pharmaceuticals (TARS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2517418569","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517418569?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 14:36","pubTimestamp":1741242964,"startTime":"0","endTime":"0","summary":"In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Tarsus Pharmaceuticals (TARS – Research Report), with a price ta...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/barclays-sticks-to-their-buy-rating-for-tarsus-pharmaceuticals-tars-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/barclays-sticks-to-their-buy-rating-for-tarsus-pharmaceuticals-tars-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TARS"],"gpt_icon":0},{"id":"2514857579","title":"Tarsus Pharmaceuticals Is Maintained at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2514857579","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514857579?lang=en_us&edition=full_marsco","pubTime":"2025-02-27 00:15","pubTimestamp":1740586500,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TARS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 26, 2025 11:15 ET (16:15 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TARS"],"gpt_icon":0},{"id":"1172093281","title":"Stock Track | Tarsus Pharmaceuticals Soars 5.74% as Strong 2024 Results Fuel Growth Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=1172093281","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172093281?lang=en_us&edition=full_marsco","pubTime":"2025-02-26 22:41","pubTimestamp":1740580886,"startTime":"0","endTime":"0","summary":"Tarsus Pharmaceuticals, Inc.  stock surged 5.74% in the pre-market session on Wednesday, driven by the company's impressive 2024 financial results and robust growth prospects for its leading product XDEMVY.The biopharmaceutical company reported stellar full-year 2024 net product sales of $180.1 million for XDEMVY, exceeding expectations and reflecting the successful execution of its commercial strategies. Key highlights included:. - Expansion of the sales force from 100 to 150 representatives, i","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Stock Track | Tarsus Pharmaceuticals Soars 5.74% as Strong 2024 Results Fuel Growth Momentum","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["TARS"],"gpt_icon":0},{"id":"2514832348","title":"Tarsus Pharmaceuticals Price Target Maintained With a $73.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2514832348","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514832348?lang=en_us&edition=full_marsco","pubTime":"2025-02-26 20:39","pubTimestamp":1740573540,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TARS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 26, 2025 07:39 ET (12:39 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TARS"],"gpt_icon":0},{"id":"2514839756","title":"Tarsus Pharmaceuticals: Strong Earnings and Growth Potential Make It a Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2514839756","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514839756?lang=en_us&edition=full_marsco","pubTime":"2025-02-26 19:59","pubTimestamp":1740571177,"startTime":"0","endTime":"0","summary":"Analyst Cory Jubinville, PhD of LifeSci Capital maintained a Buy rating on Tarsus Pharmaceuticals (TARS – Research Report), boosting the price targ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/tarsus-pharmaceuticals-strong-earnings-and-growth-potential-make-it-a-buy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/tarsus-pharmaceuticals-strong-earnings-and-growth-potential-make-it-a-buy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TARS"],"gpt_icon":0},{"id":"2514836548","title":"Tarsus Pharmaceuticals: Undervalued Growth Potential and Acquisition Appeal Reinforce Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2514836548","media":"TIPRANKS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514836548?lang=en_us&edition=full_marsco","pubTime":"2025-02-26 19:38","pubTimestamp":1740569930,"startTime":"0","endTime":"0","summary":"Analyst Oren Livnat of H.C. Wainwright reiterated a Buy rating on Tarsus Pharmaceuticals (TARS – Research Report), with a price target of $73.00. O...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/tarsus-pharmaceuticals-undervalued-growth-potential-and-acquisition-appeal-reinforce-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/tarsus-pharmaceuticals-undervalued-growth-potential-and-acquisition-appeal-reinforce-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TARS"],"gpt_icon":0},{"id":"2514983804","title":"Tarsus Pharmaceuticals price target lowered to $60 from $62 at Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2514983804","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514983804?lang=en_us&edition=full_marsco","pubTime":"2025-02-26 18:45","pubTimestamp":1740566736,"startTime":"0","endTime":"0","summary":"Barclays lowered the firm’s price target on Tarsus Pharmaceuticals (TARS) to $60 from $62 and keeps an Overweight rating on the shares following th...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tarsus-pharmaceuticals-price-target-lowered-to-60-from-62-at-barclays?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tarsus-pharmaceuticals-price-target-lowered-to-60-from-62-at-barclays?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TARS"],"gpt_icon":0},{"id":"2514865585","title":"Tarsus Pharmaceuticals Full Year 2024 Earnings: Beats Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2514865585","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514865585?lang=en_us&edition=full_marsco","pubTime":"2025-02-26 18:24","pubTimestamp":1740565461,"startTime":"0","endTime":"0","summary":"Tarsus Pharmaceuticals ( NASDAQ:TARS ) Full Year 2024 Results Key Financial Results Revenue: US$183.0m (up by US$165.5m...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tars/tarsus-pharmaceuticals/news/tarsus-pharmaceuticals-full-year-2024-earnings-beats-expecta","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TARS"],"gpt_icon":0},{"id":"2514014600","title":"Q4 2024 Tarsus Pharmaceuticals Inc Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2514014600","media":"Thomson Reuters StreetEvents","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514014600?lang=en_us&edition=full_marsco","pubTime":"2025-02-26 15:13","pubTimestamp":1740554009,"startTime":"0","endTime":"0","summary":"Bobak Azamian; Chairman of the Board, President, Chief Executive Officer, Co-Founder; Tarsus Pharmaceuticals Inc. Thank you. Before we begin, I encourage everyone to go to the investors section of the Tarsus website to view the earnings release and related materials we will be discussing today.Joining me on the call this morning are Bobby Azamian, our Chief Executive Officer and Chairman, Aziz Mottiwala, our Chief Commercial Officer, Sesha Neervannan, our Chief Operating Officer, and Jeff Farrow, our Chief Financial Officer and Chief Strategy Officer.I'd like to draw your attention to slide 3, which contains our forward-looking statements. During this call, we will be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially.I encourage you to consult the risk factors contained in our SEC filings for additional detail.With that, I will turn the c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q4-2024-tarsus-pharmaceuticals-inc-071329292.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TARS"],"gpt_icon":0},{"id":"2514001449","title":"Tarsus Pharmaceuticals Inc (TARS) Q4 2024 Earnings Call Highlights: Strong Sales Growth and ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2514001449","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514001449?lang=en_us&edition=full_marsco","pubTime":"2025-02-26 15:05","pubTimestamp":1740553522,"startTime":"0","endTime":"0","summary":"Net Product Sales: $180.1 million for the full year 2024.Bottles Dispensed: 163,000 bottles for the full year 2024.Cash and Cash Equivalents: $291.4 million at the end of 2024.Gross to Net Discount: Approximately 45% for 2024.Sales Force Expansion: Increased from 100 to 150 sales representatives.GuruFocus has detected 4 Warning Signs with TARS.For the complete transcript of the earnings call, please refer to the full earnings call transcript.Tarsus Pharmaceuticals Inc  reported over $180 million in net product sales for 2024, exceeding expectations.The company expanded its sales force from 100 to 150 representatives, increasing its reach to over 15,000 eye care physicians.XDEMVY, Tarsus Pharmaceuticals Inc 's product, now has commercial and Medicare coverage extending to more than 90% of potential patient lives.The company launched a successful direct-to-consumer advertising campaign, expanding into major network TV events, which has increased patient engagement.The gross-to-net discou","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tarsus-pharmaceuticals-inc-tars-q4-070522340.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TARS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tarsusrx.com","stockEarnings":[{"period":"1week","weight":-0.0125},{"period":"1month","weight":-0.0142},{"period":"3month","weight":-0.1188},{"period":"6month","weight":0.3002},{"period":"1year","weight":0.2126},{"period":"ytd","weight":-0.1615}],"compareEarnings":[{"period":"1week","weight":0.0567},{"period":"1month","weight":-0.0446},{"period":"3month","weight":-0.0802},{"period":"6month","weight":-0.0787},{"period":"1year","weight":0.0308},{"period":"ytd","weight":-0.089}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Tarsus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.039062},{"month":2,"riseRate":0.2,"avgChangeRate":0.010659},{"month":3,"riseRate":0.2,"avgChangeRate":-0.047875},{"month":4,"riseRate":0.4,"avgChangeRate":-0.000566},{"month":5,"riseRate":0.75,"avgChangeRate":0.001731},{"month":6,"riseRate":0.5,"avgChangeRate":-0.041248},{"month":7,"riseRate":0.5,"avgChangeRate":-0.020177},{"month":8,"riseRate":0.75,"avgChangeRate":0.027434},{"month":9,"riseRate":0.75,"avgChangeRate":0.038599},{"month":10,"riseRate":0.75,"avgChangeRate":0.129536},{"month":11,"riseRate":0.6,"avgChangeRate":0.078605},{"month":12,"riseRate":0.6,"avgChangeRate":0.141731}],"exchange":"NASDAQ","name":"Tarsus Pharmaceuticals, Inc.","nameEN":"Tarsus Pharmaceuticals, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.4","shortVersion":"4.32.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Tarsus Pharmaceuticals, Inc.(TARS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Tarsus Pharmaceuticals, Inc.(TARS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Tarsus Pharmaceuticals, Inc.,TARS,Tarsus Pharmaceuticals, Inc.股票,Tarsus Pharmaceuticals, Inc.股票老虎,Tarsus Pharmaceuticals, Inc.股票老虎国际,Tarsus Pharmaceuticals, Inc.行情,Tarsus Pharmaceuticals, Inc.股票行情,Tarsus Pharmaceuticals, Inc.股价,Tarsus Pharmaceuticals, Inc.股市,Tarsus Pharmaceuticals, Inc.股票价格,Tarsus Pharmaceuticals, Inc.股票交易,Tarsus Pharmaceuticals, Inc.股票购买,Tarsus Pharmaceuticals, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Tarsus Pharmaceuticals, Inc.(TARS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Tarsus Pharmaceuticals, Inc.(TARS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction